Imatinib mesylate: An optimization in its synthesis

Abstract

Imatinib mesylate - gleevec® is considered a major alternative for the treatment of chronic myelogenous leukemia. Clinical studies demonstrate a complete hematological response in most patients treated with this drug. The effectiveness of the drug, the high cost and the patent expiration has been responsible for the publication of numerous studies that seek to improve the synthesis of this drug. This study reports an optimization of the first synthetic process described in the literature. Batches were synthesized on a semi-pilot scale, to develop methodologies that may be available for the production of the product on an industrial scale.